- Home
- BCDA vs CISO Comparison
BCDA vs CISO Comparison
Compare BCDA & CISO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- CISO
- Stock Information
- Founded
- BCDA N/A
- CISO 2015
- Country
- BCDA United States
- CISO United States
- Employees
- BCDA N/A
- CISO N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- CISO Computer Software: Prepackaged Software
- Sector
- BCDA Health Care
- CISO Technology
- Exchange
- BCDA Nasdaq
- CISO Nasdaq
- Market Cap
- BCDA 7.9M
- CISO 8.3M
- IPO Year
- BCDA N/A
- CISO N/A
- Fundamental
- Price
- BCDA $2.68
- CISO $0.88
- Analyst Decision
- BCDA Strong Buy
- CISO
- Analyst Count
- BCDA 1
- CISO 0
- Target Price
- BCDA $25.00
- CISO N/A
- AVG Volume (30 Days)
- BCDA 73.1K
- CISO 99.5K
- Earning Date
- BCDA 11-06-2024
- CISO 11-11-2024
- Dividend Yield
- BCDA N/A
- CISO N/A
- EPS Growth
- BCDA N/A
- CISO N/A
- EPS
- BCDA N/A
- CISO N/A
- Revenue
- BCDA $428,000.00
- CISO $55,807,138.00
- Revenue This Year
- BCDA $6.92
- CISO $78.76
- Revenue Next Year
- BCDA N/A
- CISO N/A
- P/E Ratio
- BCDA N/A
- CISO N/A
- Revenue Growth
- BCDA 0.71
- CISO 29.55
- 52 Week Low
- BCDA $1.96
- CISO $0.26
- 52 Week High
- BCDA $23.25
- CISO $3.60
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- CISO 57.14
- Support Level
- BCDA $2.39
- CISO $0.77
- Resistance Level
- BCDA $2.90
- CISO $1.08
- Average True Range (ATR)
- BCDA 0.18
- CISO 0.12
- MACD
- BCDA -0.00
- CISO -0.01
- Stochastic Oscillator
- BCDA 53.70
- CISO 53.55
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.